D-threo-PDMP
Based on 1 Customer Validation
D-threo-PDMP is a potent glucoceramide synthase (GCS) inhibitor, which reduces the glycosphingolipids (such as GM3 and GD3) on the cell surface by inhibiting glycosylation, reduces the total length of the axon plexus and the number of axon branch points, and inhibits neurite growth. D-threo-PDMP inhibits the synthesis of GM3, thereby reducing the adhesion ability of B16 melanoma cells and mimicking the pathological effects of hyperglycemia/TGF-β1. D-threo-PDMP inhibits the synthesis of GD3, thereby protecting liver cells from apoptosis induced by TNF-α. D-threo-PDMP can be used to study diseases related to targeted glycosphingolipid metabolism.
For research use only. We do not sell to patients.
- Purity: 99.50%
- CAS No.: 109836-82-0
- Formula: C23H38N2O3
- Molecular Weight:390.56
-
Storage:
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Neuronal Signaling Compound Library
HY-L013
-
Anti-Cancer Compound Library
HY-L025
-
Lipid Metabolism Compound Library
HY-L091
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
D-threo-PDMP (2-14 h) inhibits the synthesis of glycosphingolipids and enhances the accumulation of ceramides, and protects hepatocytes from death induced by TNF-α[1].
D-threo-PDMP (20 μM, 24 h) significantly stimulates the proliferation of tethered glomerular mesangial cells (GMC) and also inhibit the synthesis enzyme of ganglioside, specifically reducing the level of GM3[2].
D-threo-PDMP (5-20 μM, 2 d) dose-dependently inhibits the neurite growth of rat explants[3].
D-threo-PDMP (5-40 μM, 8 d) significantly reduces the frequency of synchronous Ca2+ oscillations in cortical neurons[3].
D-threo-PDMP (10-15 μM, 20 h) inhibits the adhesion of B16 melanoma cells by blocking glycolipid synthesis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:The model of anterior brain ischemia induced by the four-vessel occlusion (4-VO) method established in male Wistar rats (200-250 g) [3]
-
Dosage:40 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice daily for 6 days
-
Result:Increased the memory impairment caused by ischemia in rats.
Chemical Information
-
CAS No. 109836-82-0
-
Appearance Oil
-
Molecular Weight 390.56
-
Formula C23H38N2O3
-
Color Colorless to off-white
-
SMILES
CCCCCCCCCC(N[C@H](CN1CCOCC1)[C@H](O)C2=CC=CC=C2)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvent & Solubility
DMSO : 200 mg/mL (512.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (12.80 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (12.80 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Carmen García-Ruiz, et al. Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice. J Clin Invest. 2003 Jan;111(2):197-208. [Content Brief]
[2]. Dong Hoon Kwak, et al. Ganglioside GM3 inhibits the high glucose- and TGF-beta1-induced proliferation of rat glomerular mesangial cells. Life Sci. 2005 Sep 30;77(20):2540-51. [Content Brief]
[3]. Hiranita T, et al. Stimulants as specific inducers of dopamine-independent σ agonist self-administration in rats. J Pharmacol Exp Ther. 2013 Oct;347(1):20-9. [Content Brief]
[4]. Inokuchi J, et al. Effects of D-threo-PDMP, an inhibitor of glucosylceramide synthetase, on expression of cell surface glycolipid antigen and binding to adhesive proteins by B16 melanoma cells. J Cell Physiol. 1989 Dec;141(3):573-83. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5604 mL | 12.8021 mL | 25.6043 mL | 64.0107 mL |
| 5 mM | 0.5121 mL | 2.5604 mL | 5.1209 mL | 12.8021 mL | |
| 10 mM | 0.2560 mL | 1.2802 mL | 2.5604 mL | 6.4011 mL | |
| 15 mM | 0.1707 mL | 0.8535 mL | 1.7070 mL | 4.2674 mL | |
| 20 mM | 0.1280 mL | 0.6401 mL | 1.2802 mL | 3.2005 mL | |
| 25 mM | 0.1024 mL | 0.5121 mL | 1.0242 mL | 2.5604 mL | |
| 30 mM | 0.0853 mL | 0.4267 mL | 0.8535 mL | 2.1337 mL | |
| 40 mM | 0.0640 mL | 0.3201 mL | 0.6401 mL | 1.6003 mL | |
| 50 mM | 0.0512 mL | 0.2560 mL | 0.5121 mL | 1.2802 mL | |
| 60 mM | 0.0427 mL | 0.2134 mL | 0.4267 mL | 1.0668 mL | |
| 80 mM | 0.0320 mL | 0.1600 mL | 0.3201 mL | 0.8001 mL | |
| 100 mM | 0.0256 mL | 0.1280 mL | 0.2560 mL | 0.6401 mL |
Powered by Bioz